Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521627-78-00

Acronym

223674

Enrollment

161

Registered

2025-09-29

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms, Lung

Brief summary

"ORR, defined as the percentage of participants with a confirmed CR or confirmed PR per RECIST 1.1 by BICR assessment ", OS, defined as the time from the date of randomization to the date of death by any cause

Interventions

DRUGTOPOTECANE ACCORD 1 mg/ml

DRUGsolution à diluer pour perfusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
"ORR, defined as the percentage of participants with a confirmed CR or confirmed PR per RECIST 1.1 by BICR assessment ", OS, defined as the time from the date of randomization to the date of death by any cause	—

Countries

Bulgaria, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Poland, Portugal, Romania, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026